# MediLink Therapeutics

Source: https://onco.cc/companies/medilink/  
OnCo record `medilink` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

MediLink developed the TMALIN ADC linker platform, licensed to Zai Lab, BioNTech, and Roche.

## Summary

MediLink Therapeutics, based in Suzhou, developed the TMALIN antibody-drug conjugate linker platform, which it has licensed to Zai Lab, BioNTech and Roche. Its pipeline includes YL201, a B7-H3 ADC in phase 3 in small-cell lung cancer, ZL-6201 against LRRC15 with Zai Lab, and a c-MET ADC deal with Roche. OnCo links it to B7-H3 as a target and to Zai Lab as a partner. Whether a linker platform company can hold on to its own lead programme rather than out-license everything is the open question. The B7-H3 target page carries the competitive picture.

## Fields

- Kind: Company
- Last checked: 2026-09-04
- Also known as: MediLink Therapeutics (Suzhou); MediLink Therapeutics
- HQ: Suzhou
- Type: biotech
- Website: https://www.medilinkthera.com

## Sources

- Official website: https://www.medilinkthera.com

## Connected records

- fronts: [Antibody-Drug Conjugates](https://onco.cc/fronts/adcs/)
- targets: [B7-H3](https://onco.cc/targets/b7h3/)
- drugs: [YL201](https://onco.cc/drugs/yl201/), [YL202](https://onco.cc/drugs/yl202/)
- trials: [A Clinical Study of YL205 in Patients With Advanced Solid Tumors](https://onco.cc/trials/nct06459973/), [A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of YL202 in Patients With BC](https://onco.cc/trials/nct06439771/), [A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC](https://onco.cc/trials/nct06241846/), [A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma(TAISHAN-301)](https://onco.cc/trials/taishan-301/), [A Phase III Study of YL201 in Relapsed Small Cell Lung Cancer（TAISHAN-302）](https://onco.cc/trials/nct06612151/), [A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors](https://onco.cc/trials/nct07208773/), [A Study of YL201 in Combination With Serplulimab in Participants With Treatment-naïve Extensive-stage Small Cell Lung Cancer](https://onco.cc/trials/nct07739758/), [A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.](https://onco.cc/trials/nct07258979/), [A Study of YL201 in Patients With Advanced Solid Tumors](https://onco.cc/trials/nct05434234/), [A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors](https://onco.cc/trials/nct07169994/), [A Study of YL202 in Patients With Advanced Solid Tumors](https://onco.cc/trials/nct07202364/), [A Study of YL202 in Selected Patients With Advanced Solid Tumors](https://onco.cc/trials/nct06107686/), [A Study of YL242 in Subjects With Advanced Solid Tumors](https://onco.cc/trials/nct07197827/), [A Study to Compare the Efficacy and Safety of YL201 With Standard Chemotherapy in Patients With Metastatic Pancreatic Cancer After Failure of Gemcitabine-Based](https://onco.cc/trials/nct07803783/), [A Study YL201 in Patients With Selected Advanced Solid Tumors](https://onco.cc/trials/nct06057922/), [Pivotal Study to Evaluate YL202 Versus Docetaxel in Patients With Locally Advanced or Metastatic EGFR Sensitive Mutation Non-Squamous Non-Small Cell Lung Cancer](https://onco.cc/trials/nct07416994/), [YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer](https://onco.cc/trials/nct07461454/)
- companies: [Zai Lab](https://onco.cc/companies/zai-lab/)

---
JSON: https://onco.cc/api/v1/entities/medilink.json